Kilkivan cattle farmer Julianne McLean is pinning her hopes on a national clinical trial after an August diagnosis of motor neurone disease cut short her future on the family farm, ABC News reported.
The 49-year-old, who has farmed cattle and hay with her husband Angus for more than 20 years, first noticed discomfort in her left leg that progressed to difficulty walking, foot drop and voice degeneration. “I know, as my body deteriorates, things will get harder and harder,” she told ABC News. “I’m just trying to stay focused on enjoying each day as much as possible.”
Julianne and Angus McLean have been together for 30 years. “The majority of the work is physical and now that I have compromised stability and balance as well as deteriorating strength, I really can’t do much of anything on the farm,” Ms McLean said. “Anytime you’re given a terminal diagnosis and that there’s officially no cure, the first thing that you lose is hope,” she said.
A new protein-based therapy developed from 25 years of University of Queensland research will advance to a phase 2 trial next year. The 75-person study will test NUN-004, a drug designed to inhibit the EphA4 receptor linked to motor neurone degeneration, at sites including Sunshine Coast University Hospital, Brisbane, Perth, Sydney and Newcastle.

In an earlier phase involving eight participants over six months, some showed signs their condition had stabilised and reported improvements in walking, balance, grip and strength. “We hope it’s fundamentally a game changer in the field,” Emeritus Professor Perry Bartlett, founder of the Queensland Brain Institute and chief scientific officer of NuNerve, told ABC News.
“I think we’ve got some reason to hope that this molecule … will change the course of this disease, both in terms of preventing progression, but also hopefully improving some of the functions.”
Sunshine Coast University Hospital director of neurology Antony Winkel, who treats McLean, said life expectancy after diagnosis is typically two to three years, with average survival of three to five years due to delayed diagnosis. Dr Winkel has worked in neurology for more than eight years.
“Currently, we don’t have a great understanding of what causes it,” Dr Winkel said. “It’s one of those really nasty diseases where it doesn’t matter what you do, you know the next day is going to be harder in some way,” he told ABC News. It’s horrendous to watch.”
MND Queensland chief executive Stacey Thorpe called the trial an “encouraging development” but cautioned that further studies are essential to establish safety and efficacy. “Developments like this provide genuine reasons for hope,” she said.
“The possibility of treatments that could preserve or even restore function is incredibly significant.” “Whether it ultimately leads to a new treatment, improves our understanding of the disease or informs future research, each carefully conducted study brings us closer to better outcomes,” she told ABC News.
McLean, who does not expect a cure in her lifetime, said the trial could buy more time with her husband and teenage daughters.
“Once you know you have limited time, yes, there’s a gift in that you do choose to spend it a lot more wisely on things that truly do matter,” she told ABC News. “It’s more time with the people I love and it’s more time for them to spend with me.”
Founded by an act of the Queensland Parliament on 10 December 1909 to mark the 50th anniversary of the colony’s separation from New South Wales, the University of Queensland is one of Australia’s six sandstone universities. Its research institutes include the Queensland Brain Institute, founded by Emeritus Professor Perry Bartlett, which has pursued the EphA4 receptor work underpinning the NUN-004 therapy for more than 25 years.
The phase 2 trial remains in the recruitment phase.